HexemBio Raised $15.5 Million for Stem Cell Therapy
The firm aims to restore aged blood stem cell function using a synthetic yolk sac environment by 2027.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Are you optimistic that new regenerative medical technologies will effectively treat age-related diseases?
HexemBio has secured $15.5 million in a funding round led by Draper Associates to advance its research in regenerating aged hematopoietic stem cells. The company recently completed a pre-IND meeting with the FDA and plans to move toward first-in-human trials in 2027.
Why it matters
HexemBio is developing a method to restore the function of hematopoietic stem cells without the complexity of genetic reprogramming. This approach targets age-related decline in blood stem cells, potentially bypassing the risks associated with traditional gene-editing techniques.
HexemBio has filed 17 patent cases with the USPTO, with 2 currently registered. The therapeutic mechanism involves exposing extracted hematopoietic stem cells to a synthetic human yolk sac environment to restore cellular function.
The players
HexemBio
A biotechnology firm developing regenerative therapies that restore function to aged hematopoietic stem cells.
Draper Associates
A venture capital firm that focuses on early-stage investments in technology and biotechnology companies.
Korean Investment Partners
A global venture capital investor that recently contributed $2 million to HexemBio's latest funding round.
The details
The technology works by mimicking the environment of a human yolk sac to rejuvenate aging hematopoietic stem cells—the precursor cells responsible for producing all blood and immune cells. By utilizing this synthetic environment, the process aims to restore cellular function without employing genetic reprogramming, which typically involves altering the cell's DNA. The company has secured FDA Orphan Drug Designation for its approach, signaling a specialized development path for rare conditions related to blood cell depletion.
Timeline
July 2025: HexemBio received FDA Orphan Drug Designation.
January 2026: The company completed a pre-IND meeting with the FDA.
September 22, 2026: Korean Investment Partners announced its $2 million investment.
2027: HexemBio aims to initiate first-in-human dosing.
The Tech Race
The FDA Orphan Drug Designation program provides a clear regulatory pathway for HexemBio as it seeks to treat rare conditions linked to aged stem cell decline. Securing this status marks a critical milestone in the company's efforts to move its regenerative therapy into clinical trials.
The company's therapy is currently in the research and regulatory stage with human trials planned for 2027. Patients and clinicians should monitor for upcoming clinical trial recruitment once the firm receives formal FDA clearance to move forward with human testing.
The takeaway
HexemBio's progress in restoring stem cell function without genetic modification represents a potential shift in regenerative medicine. Interested observers should monitor the progress of their planned first-in-human trials in 2027 for initial safety and efficacy results.
Further reading
For more developments in this field, visit Biotech.
Source note: This article includes information reported by 조선일보.
Live Poll
Are you optimistic that new regenerative medical technologies will effectively treat age-related diseases?
